Literature DB >> 27086035

Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia.

Abdul Salam Khan1, Mohammad Hojjat-Farsangi1, Amir Hossein Daneshmanesh1, Lotta Hansson1,2, Parviz Kokhaei1,3, Anders Österborg1,2, Håkan Mellstedt4,5, Ali Moshfegh1.   

Abstract

Dishevelled (DVL) proteins are components of the Wnt signalling pathways, and increased expression is associated with various malignancies. Information on DVLs in chronic lymphatic leukaemia (CLL) is limited. The aim of the present study was to investigate the role of DVLs in CLL cells and association with Wnt pathways downstream of ROR1. DVL1, 2 and 3 were exclusively expressed in CLL cells as compared to normal peripheral blood mononuclear cells (PBMCs). The expression of DVL1 and DVL3 proteins was significantly more pronounced in progressive than in non-progressive disease (p < 0.01), whereas the level of DVL2 was significantly higher in non-progressive as compared to progressive disease (p < 0.001). Treatment of CLL cells with anti-ROR1 specific monoclonal antibodies induced dephosphorylation of ROR1 as well as of tyrosine and serine residues of both DVL2 and DVL3. However, gene silencing of DVLs in the CLL cell line (EHEB) did not induce detectable apoptosis. Non-progressive CLL patients had a different protein activity pattern with regard to Wnt signalling pathway proteins as GSK-3β, β-catenin and AKT as compared to progressive disease. The DVL2 protein may play a role in the activation of signalling pathways in CLL during early stages of the disease, while DVL1 and 3 may have a role in later phases of the leukaemia.

Entities:  

Keywords:  CLL; DVL; ROR1; Wnt

Mesh:

Substances:

Year:  2016        PMID: 27086035     DOI: 10.1007/s13277-016-5039-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  50 in total

1.  Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis.

Authors:  Dylan T Jones; Kanagasabai Ganeshaguru; Robert J Anderson; Trevor R Jackson; K Richard Bruckdorfer; Sylvia Y Low; Lars Palmqvist; H Grant Prentice; A Victor Hoffbrand; Atul B Mehta; R Gitendra Wickremasinghe
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

2.  Wnt-5a induces Dishevelled phosphorylation and dopaminergic differentiation via a CK1-dependent mechanism.

Authors:  Vítezslav Bryja; Gunnar Schulte; Nina Rawal; Alexandra Grahn; Ernest Arenas
Journal:  J Cell Sci       Date:  2007-01-23       Impact factor: 5.285

Review 3.  Dishevelled: The hub of Wnt signaling.

Authors:  Chan Gao; Ye-Guang Chen
Journal:  Cell Signal       Date:  2009-12-13       Impact factor: 4.315

4.  Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia.

Authors:  Ali Memarian; Mohammad Hojjat-Farsangi; Hossein Asgarian-Omran; Vahid Younesi; Mahmood Jeddi-Tehrani; Ramazan Ali Sharifian; Jalal Khoshnoodi; Seyed Mohsen Razavi; Hodjatallah Rabbani; Fazel Shokri
Journal:  Leuk Lymphoma       Date:  2009-12

5.  Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

Authors:  Aleksandar Petlickovski; Luca Laurenti; Xiaoping Li; Sara Marietti; Patrizia Chiusolo; Simona Sica; Giuseppe Leone; Dimitar G Efremov
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

6.  LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.

Authors:  Albert Gutierrez; Renee C Tschumper; Xiaosheng Wu; Tait D Shanafelt; Jeanette Eckel-Passow; Paul M Huddleston; Susan L Slager; Neil E Kay; Diane F Jelinek
Journal:  Blood       Date:  2010-07-01       Impact factor: 22.113

Review 7.  Wnt/β-catenin pathway in bone cancers.

Authors:  Jian Tian; Hongbo He; Guanghua Lei
Journal:  Tumour Biol       Date:  2014-08-13

8.  Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.

Authors:  Pauline Y Huang; Oliver G Best; Juhura G Almazi; Larissa Belov; Zadie A Davis; Aneela Majid; Martin J Dyer; Dana Pascovici; Stephen P Mulligan; Richard I Christopherson
Journal:  Leuk Lymphoma       Date:  2014-01-24

9.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.

Authors:  Tetsuya Fukuda; Liguang Chen; Tomoyuki Endo; Li Tang; Desheng Lu; Januario E Castro; George F Widhopf; Laura Z Rassenti; Mark J Cantwell; Charles E Prussak; Dennis A Carson; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

10.  Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

Authors:  Sivasubramanian Baskar; Ka Yin Kwong; Thomas Hofer; Jessica M Levy; Michael G Kennedy; Elinor Lee; Louis M Staudt; Wyndham H Wilson; Adrian Wiestner; Christoph Rader
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

View more
  10 in total

1.  Dishevelled proteins and CYLD reciprocally regulate each other in CML cell lines.

Authors:  Ceyda Çalışkan; Melek Pehlivan; Zeynep Yüce; Ogun Sercan
Journal:  Mol Biol Rep       Date:  2017-08-24       Impact factor: 2.316

Review 2.  Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.

Authors:  Pavlína Janovská; Vítězslav Bryja
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

Review 3.  Dishevelled: A masterful conductor of complex Wnt signals.

Authors:  Monica Sharma; Isabel Castro-Piedras; Glenn E Simmons; Kevin Pruitt
Journal:  Cell Signal       Date:  2018-03-17       Impact factor: 4.315

Review 4.  Regulation of spermatid polarity by the actin- and microtubule (MT)-based cytoskeletons.

Authors:  Linxi Li; Baiping Mao; Siwen Wu; Qingquan Lian; Ren-Shan Ge; Bruno Silvestrini; C Yan Cheng
Journal:  Semin Cell Dev Biol       Date:  2018-07-12       Impact factor: 7.727

5.  Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia.

Authors:  Hana Plešingerová; Pavlína Janovská; Archana Mishra; Lucie Smyčková; Lucie Poppová; Antonín Libra; Karla Plevová; Petra Ovesná; Lenka Radová; Michael Doubek; Šárka Pavlová; Šárka Pospíšilová; Vítězslav Bryja
Journal:  Haematologica       Date:  2017-11-09       Impact factor: 9.941

6.  Molecular genetics and targeted therapy of WNT-related human diseases (Review).

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Int J Mol Med       Date:  2017-07-19       Impact factor: 4.101

Review 7.  Targeting Casein Kinase 1 (CK1) in Hematological Cancers.

Authors:  Pavlína Janovská; Emmanuel Normant; Hari Miskin; Vítězslav Bryja
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

Review 8.  Wnt/β-catenin signaling in cancers and targeted therapies.

Authors:  Fanyuan Yu; Changhao Yu; Feifei Li; Yanqin Zuo; Yitian Wang; Lin Yao; Chenzhou Wu; Chenglin Wang; Ling Ye
Journal:  Signal Transduct Target Ther       Date:  2021-08-30

9.  Antitumor Effect of Sclerostin against Osteosarcoma.

Authors:  Hirokazu Ideta; Kazushige Yoshida; Masanori Okamoto; Jun Sasaki; Munehisa Kito; Kaoru Aoki; Yasuo Yoshimura; Shuichiro Suzuki; Atsushi Tanaka; Akira Takazawa; Hisao Haniu; Takeshi Uemura; Takashi Takizawa; Atsushi Sobajima; Takayuki Kamanaka; Jun Takahashi; Hiroyuki Kato; Naoto Saito
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

10.  Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia.

Authors:  Maurizio Mangolini; Frederik Götte; Andrew Moore; Tim Ammon; Madlen Oelsner; Gloria Lutzny-Geier; Ludger Klein-Hitpass; James C Williamson; Paul J Lehner; Jan Dürig; Michael Möllmann; Lívia Rásó-Barnett; Katherine Hughes; Antonella Santoro; Simón Méndez-Ferrer; Robert A J Oostendorp; Ursula Zimber-Strobl; Christian Peschel; Daniel J Hodson; Marc Schmidt-Supprian; Ingo Ringshausen
Journal:  Nat Commun       Date:  2018-09-21       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.